Alder BioPharmaceuticals announced that eptinezumab, its lead investigational product candidate for migraine prevention targeting calcitonin gene-related peptide (CGRP), met the primary endpoint in its pivotal Phase 3 PROMISE 2 clinical trial with very high statistical significance for both dose levels tested in the trial following a single quarterly infusion.    In addition, eptinezumab met all key secondary endpoints with very high statistical significance vs. placebo including prevent...